Taysha Gene Therapies Names Sean P. Nolan as CEO and Sukumar Nagendran, M.D., as Chief Medical Officer
December 31, 2022
Trending News 🌥️
TSHA Stock Fair Value – Taysha Gene Therapies ($NASDAQ:TSHA) is a biopharmaceutical company focused on developing and commercializing novel gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations. The company has recently announced the appointment of Sean P. Nolan as its new CEO and Sukumar Nagendran, M.D., as Chief Medical Officer. He has been involved in the development and commercialization of several products including cardiovascular, neurology, and immunology, as well as leading large business units across multiple continents. His previous roles include President and CEO of Aquinox Pharmaceuticals and Senior Vice President and Global Head of the Neurology Franchise at UCB. He has held leadership roles in both public and private companies, most recently serving as Executive Vice President and Chief Medical Officer at Audentes Therapeutics.
He has been involved in the development of several products in the areas of neuromuscular and metabolic diseases, with a particular focus on rare diseases. He has also held positions at Alexion Pharmaceuticals, Genentech, and Takeda Pharmaceuticals. The appointments of Sean P. Nolan and Dr. Nagendran demonstrate Taysha Gene Therapies’ commitment to advancing its mission of developing novel gene therapies to help treat patients with rare genetic monogenic diseases of the central nervous system. With their combined experience, they are well-positioned to lead the company into its next phase of growth and success.
Price History
He has a proven track record of building successful teams and launching innovative products. As the CEO of TAYSHA Gene Therapies, Mr. Nolan will be responsible for leading the strategic planning and business operations of the company. Dr. Nagendran is a board-certified pediatric neurologist with extensive experience in clinical drug development, research and regulation. He has held several leadership positions at pharmaceutical companies, including Shire, where he was Vice President of Clinical Development for the Neurology franchise. As Chief Medical Officer at TAYSHA Gene Therapies, Dr. Nagendran will be responsible for overseeing the clinical development of the company’s gene therapy products.
These appointments come at an important time for TAYSHA Gene Therapies as the company prepares to launch its first product in 2021. The stock opened at $2.2 on Monday and closed at $1.9, a drop of 9.3% from the prior closing price of 2.1. The market’s reaction to the news indicates confidence in the company’s new leadership team and their ability to build upon TAYSHA Gene Therapies’ success in the coming years. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for TSHA. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -160.68 | – |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for TSHA. More…
| Operations | Investing | Financing |
| -142.93 | -31.08 | 19.54 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for TSHA. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 111.47 | 100.34 | 0.27 |
Key Ratios Snapshot
Some of the financial key ratios for TSHA are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | – |
| FCF Margin | ROE | ROA |
| – | -447.6% | -88.0% |
VI Analysis – TSHA Stock Fair Value
TAYSHA GENE THERAPIES is a company whose financials can be easily assessed and tracked using the VI app. According to the app, the fair value of TAYSHA GENE THERAPIES shares is estimated to be around $1.1. This is based on the long term potential of the company. However, currently, the stock is trading at $1.9, an overvaluation of 72%. This presents an opportunity for investors to take advantage of the discrepancy between the current market price and the fair value. Investors should keep in mind that stock prices are subject to market fluctuations, and that TAYSHA GENE THERAPIES’ stock could move up or down depending on a variety of factors. Therefore, it is important to do thorough research before investing in any company. Additionally, investors should pay attention to the company’s fundamentals, such as earnings, revenue, cash flow and other key indicators, to get a better understanding of the company’s financial health. More…
VI Peers
The Company focuses on developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations. Taysha Gene Therapies Inc’s competitors include uniQure NV, Inozyme Pharma Inc, Sorrento Therapeutics Inc.
– uniQure NV ($NASDAQ:QURE)
UniQure NV is a Dutch holding company that operates in the biopharmaceutical industry. The company researches, develops, and commercializes gene therapies. As of 2022, UniQure NV has a market cap of 884.11M and a Return on Equity of -12.84%. The company’s products are used to treat patients with rare and often fatal diseases.
– Inozyme Pharma Inc ($NASDAQ:INZY)
Inozyme Pharma Inc is a biopharmaceutical company that focuses on developing treatments for disorders of calcification. The company’s lead product candidate, ENB-0040, is in clinical development for the treatment of X-linked hypophosphatemia (XLH), a rare genetic disorder that leads to defective bone formation and kidney dysfunction. Inozyme also has two other product candidates in development for the treatment of autosomal dominant hypophosphatemic rickets (ADHR) and tumoral calcinosis (TC).
Inozyme Pharma Inc has a market cap of 88.72M as of 2022. The company’s Return on Equity is -48.16%. Inozyme Pharma Inc focuses on developing treatments for disorders of calcification. The company’s lead product candidate, ENB-0040, is in clinical development for the treatment of X-linked hypophosphatemia (XLH), a rare genetic disorder that leads to defective bone formation and kidney dysfunction. Inozyme also has two other product candidates in development for the treatment of autosomal dominant hypophosphatemic rickets (ADHR) and tumoral calcinosis (TC).
– Sorrento Therapeutics Inc ($NASDAQ:SRNE)
Sorrento Therapeutics Inc. is a biopharmaceutical company that engages in the research, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases. The company’s market cap is 715.42M as of 2022 and has a return on equity of -190.34%. Sorrento Therapeutics is headquartered in San Diego, California.
Summary
Investing in Taysha Gene Therapies can be a great opportunity for those looking to capitalise on a potentially lucrative healthcare sector. The company has recently made some high-profile appointments to its executive team, with the addition of Sean P. Nolan as CEO and Sukumar Nagendran, M.D., as Chief Medical Officer. This suggests that the company is set to continue to grow and evolve, creating new opportunities for investors. Taysha Gene Therapies focuses on developing gene therapies to treat rare and devastating neurological disorders, and its current products have the potential to have a major impact on the lives of those affected. The company’s commitment to innovation and research could lead to significant advances in the industry, and consequently, increased market share and profits. Investing in Taysha Gene Therapies also offers investors the potential for growth in the long run. With its focus on developing treatments for rare neurological disorders, the company has an opportunity to create treatments that are not available anywhere else. This could result in a unique competitive advantage and the potential for increased profits. Furthermore, the company is well-positioned to benefit from any future advances in gene therapy technology, which could further enhance its potential for growth. Overall, investing in Taysha Gene Therapies is an excellent option for those looking to capitalize on the healthcare sector. With its commitment to innovation and research, as well as its potential for long-term growth, this company could be an excellent choice for investors.
However, it is important to remember that investing in any stock carries risk, so it is important to do your own research before making any decisions.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
